CVID subjects sequenced in 3 cohorts
| Parameters . | US . | Sweden . | Iran . |
|---|---|---|---|
| N | 235 | 128 | 208 |
| Males, n | 101 | 63 | 113 |
| Females, n | 134 | 65 | 95 |
| Median age (range), y | 44 (5-85) | 49.5 (4-90) | 9 (1-65) |
| Known consanguineous, n (%) | 0 | 0 | 129 (63) |
| Relatives with immune defects, n | 14 | 5 | 23 |
| Gene candidates identified, n (%) | 74 (31) | 46 (36) | 112 (54) |
| Parameters . | US . | Sweden . | Iran . |
|---|---|---|---|
| N | 235 | 128 | 208 |
| Males, n | 101 | 63 | 113 |
| Females, n | 134 | 65 | 95 |
| Median age (range), y | 44 (5-85) | 49.5 (4-90) | 9 (1-65) |
| Known consanguineous, n (%) | 0 | 0 | 129 (63) |
| Relatives with immune defects, n | 14 | 5 | 23 |
| Gene candidates identified, n (%) | 74 (31) | 46 (36) | 112 (54) |